Company Filing History:
1 out of 20 
1 out of 26 Years Active: 2020
Title: Daofei Li: Innovator in Pharmaceutical Development
Introduction
Daofei Li is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of EGFR inhibitors. His work has the potential to impact cancer treatment and improve patient outcomes.
Latest Patents
Daofei Li holds a patent for an EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, along with its use. This patent details a polymorph, a pharmaceutically acceptable salt, or a prodrug of N-(2-(4-(dimethylamino)piperid-1-yl)-5-(5-fluoro-4-(1-methyl-1H-pyrazol-4-yl)pyrimidin-2-ylamino)-4-methoxy phenyl) acrylamide. Additionally, it includes a pharmaceutical composition containing the inhibitor and its applications.
Career Highlights
Throughout his career, Daofei Li has worked with notable companies such as Shanghai Haiyan Pharmaceutical Technology Co., Ltd. and Yangtze River Pharmaceutical Group Co., Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation.
Collaborations
Daofei Li has collaborated with talented individuals in the field, including Jiong Lan and Taotao Jiang. These partnerships have contributed to his success and the advancement of his research.
Conclusion
Daofei Li is a key figure in pharmaceutical innovation, with a focus on EGFR inhibitors that hold promise for cancer treatment. His contributions and collaborations continue to shape the future of medicine.